Genetic Technology Alert. Variant of Gene Type Linking Cholesterol with Cardiovascular Disease Identified; Cancer Treatment as a Result of Telomere Inhibition

USD 250

* Required Fields

USD 250

PAY BY INVOICE

Be the first to review this product

This issue profiles research that has identified a variant of gene type linking cholesterol with cardiovascular disease; a genetic variant that identifies the likelihood of patient's response to treatment for multiple sclerosis, and cancer treatment by telomere inhibition.

Table of Contents

Genetic Technology Alert. Variant of Gene Type Linking Cholesterol with Cardiovascular Disease Identified; Cancer Treatment as a Result of Telomere InhibitionIn This Issue1. VARIANT OF GENE TYPE LINKING CHOLESTEROL WITH CARDIOVASCULAR DISEASE IDENTIFIED 2. GENETIC VARIANT IDENTIFIES THE LIKELIHOOD OF PATIENT'S RESPONSE TO TREATMENT FOR MULTIPLE SCLEROSIS3. CANCER TREATMENT AS A RESULT OF TELOMERE INHIBITION4. KEY PATENTS COVERING RECENT INVENTIONS FOR THE TREATMENT OF MARFAN SYNDROME5. TECHVISION 2015




Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.